JP Morgan Chase
INM icon

JP Morgan Chase’s InMed Pharmaceuticals INM Stock Holding History

JP Morgan Chase’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15
Closed -$36K – 6458
2021
Q1 		$36K Buy
15
+2
+15% +$4.29K ﹤0.01% 5603
2020
Q4 		$21K Buy
+13
New +$21.1K ﹤0.01% 5289

Other funds holding INM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RFA
Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return

JP Morgan Chase's INM Position: Q2 2021 in Review

JP Morgan Chase sold out of InMed Pharmaceuticals (INM) in Q2 2021, closing a stake of 15 shares — an estimated $36K sold.

JP Morgan Chase first reported a position in INM in Q4 2020 and held it in 2 quarters. The position peaked at $36K in Q1 2021. 13 funds tracked by Wall St. Rank hold INM as of Q2 2021.

  • JP Morgan Chase reported no remaining InMed Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • JP Morgan Chase sold 15 InMed Pharmaceuticals shares in Q2 2021, an estimated $36K.
  • JP Morgan Chase first reported a position in InMed Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • JP Morgan Chase's InMed Pharmaceuticals position peaked at $36K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2021.

Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.